Monika Engelhardt

Summary

Affiliation: University of Freiburg
Country: Germany

Publications

  1. doi request reprint Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches
    Monika Engelhardt
    Hematology and Oncology Department, University of Freiburg Medical Center, Freiburg, Germany
    Leuk Lymphoma 51:1424-43. 2010
  2. ncbi request reprint Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture
    M Engelhardt
    James Ewing Laboratory of Developmental Hematopoiesis, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 60:610-7. 2000
  3. ncbi request reprint Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation
    M Engelhardt
    University of Freiburg Medical Center, Division Hematology Oncology, Freiburg, Germany
    Ann Hematol 80:201-8. 2001
  4. ncbi request reprint Telomere length and hTERT expression in patients with acute myeloid leukemia correlate with karyotypic instability
    Monika Engelhardt
    Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Haematologica 90:289B. 2005
  5. ncbi request reprint Telomeres and telomerase in normal and leukemic hematopoietic cells
    Monika Engelhardt
    Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Leuk Res 28:1001-4. 2004
  6. doi request reprint Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal
    Martina Kleber
    Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, Freiburg, Germany
    Clin Lymphoma Myeloma Leuk 12:38-48. 2012
  7. doi request reprint Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization
    Josefina Udi
    Department of Haematology and Oncology, Freiburg University Medical Centre, Freiburg, Germany
    Br J Haematol 161:104-16. 2013
  8. doi request reprint Does colorectal cancer in ulcerative colitis patients constitute a risk for chemotherapy refractoriness?:a systemic approach by detailed analysis via the electronic tumor base documentation system
    Monika Engelhardt
    Department of Hematology and Oncology, Clinical Trials Unit, University Medical Center Freiburg, Germany
    Onkologie 34:688-94. 2011
  9. pmc Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies
    Julia Schueler
    Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany Department for Invivo Tumorbiology, Oncotest, Freiburg, Germany
    PLoS ONE 8:e79939. 2013
  10. ncbi request reprint Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature
    Barbara N Gross
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Pharmacotherapy 33:1117-25. 2013

Collaborators

Detail Information

Publications42

  1. doi request reprint Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches
    Monika Engelhardt
    Hematology and Oncology Department, University of Freiburg Medical Center, Freiburg, Germany
    Leuk Lymphoma 51:1424-43. 2010
    ..This report reviews recent clinical advances in the treatment strategies available for MM and provides an overview of the state of the art management of patients with MM...
  2. ncbi request reprint Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture
    M Engelhardt
    James Ewing Laboratory of Developmental Hematopoiesis, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 60:610-7. 2000
    ..Telomere shortening during ex vivo expansion correlated with low levels of TA, particularly in chronic leukemic and MDS progenitors where telomerase was insufficient to protect against telomere bp loss during intense proliferation...
  3. ncbi request reprint Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation
    M Engelhardt
    University of Freiburg Medical Center, Division Hematology Oncology, Freiburg, Germany
    Ann Hematol 80:201-8. 2001
    ..Taken together, our results demonstrate that intermediate-dose rhG-CSF sufficiently mobilizes > or =4x10(6)/kg x bw CD34+ cells with use of LVA and that especially younger donors display increased CD34+ cell numbers...
  4. ncbi request reprint Telomere length and hTERT expression in patients with acute myeloid leukemia correlate with karyotypic instability
    Monika Engelhardt
    Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Haematologica 90:289B. 2005
  5. ncbi request reprint Telomeres and telomerase in normal and leukemic hematopoietic cells
    Monika Engelhardt
    Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Leuk Res 28:1001-4. 2004
    ..Their results underline the importance to study telomere biology together with cytogenetics, genomic and proteomic profiling as prognostic factors, in order to improve risk-adapted therapy of MDS and AML pts...
  6. doi request reprint Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal
    Martina Kleber
    Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, Freiburg, Germany
    Clin Lymphoma Myeloma Leuk 12:38-48. 2012
    ..Renal impairment (RI) is a dreaded complication in multiple myeloma (MM) and has been associated with decreased progression-free survival (PFS) and overall survival (OS)...
  7. doi request reprint Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization
    Josefina Udi
    Department of Haematology and Oncology, Freiburg University Medical Centre, Freiburg, Germany
    Br J Haematol 161:104-16. 2013
    ....
  8. doi request reprint Does colorectal cancer in ulcerative colitis patients constitute a risk for chemotherapy refractoriness?:a systemic approach by detailed analysis via the electronic tumor base documentation system
    Monika Engelhardt
    Department of Hematology and Oncology, Clinical Trials Unit, University Medical Center Freiburg, Germany
    Onkologie 34:688-94. 2011
    ..Ulcerative colitis (UC) patients may develop colorectal cancer (CRC), especially with pancolitis and longer UC duration. The question whether CRC with underlying UC has a dismal prognosis remains unsettled...
  9. pmc Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies
    Julia Schueler
    Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany Department for Invivo Tumorbiology, Oncotest, Freiburg, Germany
    PLoS ONE 8:e79939. 2013
    ..We systematically analyzed multiple myeloma (MM) cell lines and patient bone marrow cells for their engraftment capacity in immunodeficient mice and validated the response of the resulting xenografts to antimyeloma agents...
  10. ncbi request reprint Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature
    Barbara N Gross
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Pharmacotherapy 33:1117-25. 2013
    ..To evaluate the incidence of posaconazole serum levels below 700 μg/L, the rate of breakthrough infections during posaconazole prophylaxis, and factors influencing posaconazole exposure in daily clinical practice...
  11. ncbi request reprint Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome
    Martina Kleber
    Department of Hematology, Oncology and Stem Cell Transplantation, University Freiburg Medical Center, Freiburg, Germany
    Clin Lymphoma Myeloma Leuk 13:541-51. 2013
    ..The outcomes of MM patients vary considerably and depend on a variety of host- and disease-related risks. As yet, a comorbidity risk index in MM patients has neither been standardized nor validated...
  12. ncbi request reprint Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma
    Monika Engelhardt
    Department of Hematology and Oncology, University Medical Center Freiburg, Hugstetterstr 55, 79106 Freiburg, Germany
    Anticancer Res 29:4745-50. 2009
    ..Justified by these results it was possible to convince the patient that a more intensive therapy approach, including auto-SCT, local irradiation and thalidomide maintenance, was appropriate...
  13. doi request reprint Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy
    Martina Kleber
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Leuk Lymphoma 53:1057-61. 2012
    ....
  14. ncbi request reprint Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: association with disease characteristics and variation in different cell compartments
    Josefina Udi
    Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
    Leuk Res 35:1265-8. 2011
    ..Endothelial cells differed in BM-, PB- and LP-specimens, albeit seemed less associated with unfavorable prognostic MM-parameters. Our data suggest that especially VEGFR2(+)-cells and mature EPCs in MM are of value to explore further...
  15. pmc The 3' untranslated region of the cyclin B mRNA is not sufficient to enhance the synthesis of cyclin B during a mitotic block in human cells
    Dominik Schnerch
    Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany
    PLoS ONE 8:e74379. 2013
    ..A better understanding of how the equilibrium of cyclin B is regulated in mitosis may contribute to the development of improved therapeutic approaches to prevent mitotic slippage in cancer cells treated with antimitotic agents. ..
  16. doi request reprint Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia
    Hartmut Bertz
    Department of Hematology and Oncology, Albert Ludwigs University Medical Center Freiburg, Hugstetter Strasse 55, Freiburg, Germany
    Biol Blood Marrow Transplant 18:894-902. 2012
    ..PBSC as a graft source has a significant favorable influence on survival...
  17. ncbi request reprint Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance
    Julia Horn
    Department of Hematology and Oncology, University Medical Center Freiburg, Hugstetterstr 55, 79106 Freiburg, Germany
    Ann Hematol 91:1579-86. 2012
    ..6--n.r.), respectively. We conclude that R-B is a feasible and safe therapy option in a-B-NHL patients not qualifying for R-CHOP but needs to be further assessed in larger subsequent trials, these currently being under way...
  18. doi request reprint Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome
    Ba Thanh Truc Ngo
    Department of Hematology and Oncology, University Medical Center, Freiburg, Germany
    Leuk Lymphoma 51:1632-42. 2010
    ..0011). Our study is the first to suggest that overexpressed CCND1 in MM is an independent prognostic marker associated with a more durable response to bortezomib. These preliminary results warrant a larger study...
  19. doi request reprint Preclinical models of multiple myeloma: a critical appraisal
    Julia Schuler
    Freiburg University Medical Center UKF, Department head in vivo tumorbiology, Oncotest GmbH, Freiburg, Germany
    Expert Opin Biol Ther 13:S111-23. 2013
    ..Predicting whether a potential new anticancer agent will have a positive therapeutic index in patients remains a challenge...
  20. ncbi request reprint Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine)
    Michael Lubbert
    Department of Hematology Oncology, University of Freiburg, Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
    Leuk Res 28:1267-71. 2004
    ..In conclusion, restoration of nonclonal hematopoiesis may be the predominant effect of DAC both in early and late stages of treatment, at least in patients achieving a hematologic and cytogenetic response...
  21. ncbi request reprint Side-population cells from different precursor compartments
    Yalin Guo
    University of Freiburg Medical Center, Department of Hematology Oncology, D 79106 Freiburg, Germany
    J Hematother Stem Cell Res 12:71-82. 2003
    ..We conclude that human primitive hematopoietic cells can be isolated via Hoechst staining and that SP cells of various human sources show substantial differences and represent a rare CD34(-) population with stem cell potential...
  22. doi request reprint Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients
    Martina Kleber
    Department of Hematology and Oncology, Medical Center, University of Freiburg Medical Center, Germany
    Eur J Haematol 83:519-27. 2009
    ..Renal impairment (RI) is postulated as one negative prognostic factor in multiple myeloma (MM). The study aim was to detect the best way to define RI and the impact of different RI stages on MM outcome...
  23. ncbi request reprint Characterization of in vitro growth of multiple myeloma cells
    Mihaela Zlei
    Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
    Exp Hematol 35:1550-61. 2007
    ..To develop an in vitro culture system for rapid assessment of multiple myeloma (MM) cell growth...
  24. ncbi request reprint Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis
    Barbara Metzke
    Department of Hematology and Oncology, University Medical Center Freiburg, Hugstetter Str 55, D 79106 Freiburg, Germany
    Pharmacoepidemiol Drug Saf 21:953-63. 2012
    ..To assess the role of systemic antifungal drugs as well as the frequency of potential drug interactions and adverse drug events of commonly used antifungals in an unselected haematology/oncology patient cohort...
  25. doi request reprint Monitoring APC/C activity in the presence of chromosomal misalignment in unperturbed cell populations
    Dominik Schnerch
    Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany
    Cell Cycle 11:310-21. 2012
    ..Since chromosomal misalignment is a rare event, the ability to study entire cell populations enabled us to monitor for the first time SAC surveillance in living cells without the need of highly artificial perturbation by spindle poisons...
  26. ncbi request reprint CD34- hematopoietic stem cells: current concepts and controversies
    Yalin Guo
    Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Stem Cells 21:15-20. 2003
    ..In this review, current concepts on murine and human CD34(-) HSCs and their relationship with CD34(+) HSCs are discussed...
  27. doi request reprint Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma
    Jens Hasskarl
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Leuk Lymphoma 52:247-59. 2011
    ..Age ≥60 years was a confounding covariable with a HR of 2.021 (95% CI 1.6-2.6)...
  28. ncbi request reprint Telomere maintenance in human B lymphocytes
    Uwe M Martens
    Freiburg University Medical Centre, Department of Haematology Oncology, Germany
    Br J Haematol 119:810-8. 2002
    ..Our observations support the concept that telomere dynamics in B cells are distinct from other haematopoietic cell lineages and that telomere elongation may play an essential role in the generation of long-term B memory cells...
  29. ncbi request reprint Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey
    Nadir Ghanem
    Department of Diagnostic Radiology, University Hospital Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    Eur Radiol 16:1005-14. 2006
    ..Therefore, whole-body MRI should be performed as an additional method of exactly staging PCN patients and - with more data in the field - may even prove to be an alternate and more sensitive staging procedure than RSS in PCN patients...
  30. doi request reprint Pomalidomide
    Monika Engelhardt
    Hematology and Oncology, University of Freiburg, Hugstetterstr 55, 79106, Freiburg, Germany
    Recent Results Cancer Res 201:359-72. 2014
    ..Due to its potency, pomalidomide was approved by the US Food and Drug Administration (FDA) for RRMM in 2/2013 and has also been approved by the European Medicines Agency (EMA). ..
  31. doi request reprint Management of multiple myeloma in pregnancy: strategies for a rare challenge
    Benjamin Kasenda
    Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
    Clin Lymphoma Myeloma Leuk 11:190-7. 2011
    ..Intensified postpartum anti-myeloma therapy should be induced as soon as possible to efficiently reduce myeloma burden and avoid organ damage in these young females...
  32. doi request reprint European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
    Monika Engelhardt
    Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Leuk Lymphoma 51:2006-11. 2010
    ..v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM...
  33. ncbi request reprint Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7
    Claudia I Muller
    Department of Haematology Oncology, University of Freiburg Medical Center, Hugstetter Strasse 55, D 79106 Freiburg, Germany
    Eur J Haematol 69:115-9. 2002
    ..J. Haematol. 2001: 66: 66-69). Our report of an MDS with trilineage dysplasia and these karyotypic changes associated with DI indicates that this new entity may also include preleukemic cases...
  34. doi request reprint Ruxolitinib
    Heiko Becker
    University Freiburg Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany
    Recent Results Cancer Res 201:249-57. 2014
    ..Several further JAK inhibitors are currently studied in myelofibrosis or other immuno-inflammatory diseases. ..
  35. ncbi request reprint Primary (AL) amyloidosis in plasma cell disorders
    Antonia M S Müller
    Department of Hematology Oncology, University Medical Center Freiburg, Hugstetterstr 55, D 79106 Freiburg, Germany
    Oncologist 11:824-30. 2006
    ..This may facilitate earlier diagnosis, and thus allow initiation of prompt and specific therapies, which are indispensable in order to improve disease prognosis...
  36. ncbi request reprint State of the art therapy in multiple myeloma and future perspectives
    Ulrich Denz
    Hematology and Oncology Department, University of Freiburg Medical Center, Hugstetter Strasse 55, 79106 Freiburg, Germany
    Eur J Cancer 42:1591-600. 2006
    ..These strategies are incrementally integrated into modern MM care. This review considers recent clinical advancements in anti-myeloma strategies and provides an overview of the state of the art management of MM patients...
  37. doi request reprint Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment
    Anna Markert
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Int J Cancer 124:722-8. 2009
    ..9%, we recommend our efficient surveillance system as an important safety check, thereby ensuring that chemotherapies are delivered error-free to cancer patients...
  38. ncbi request reprint Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma
    Monika Engelhardt
    Haematologica 91:274-6. 2006
    ..From an analysis of five MM families scheduled for allogeneic SCT, monoclonal B-cell disease was detected in 8/27 siblings...
  39. ncbi request reprint Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim
    Andreas Jakob
    Ann Hematol 84:694-5. 2005
  40. ncbi request reprint Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
    Eva Susanne Strobel
    Ann Hematol 84:830-2. 2005
  41. ncbi request reprint Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
    Martin Kropff
    Department of Medicine Haematology and Oncology, University of Muenster, Muenster, Germany
    Br J Haematol 138:330-7. 2007
    ..Bortezomib combined with DEX and CY is a highly effective treatment for relapsed MM at an acceptable rate of grade 3/4 AE. Antiviral prophylaxis appears to be mandatory...
  42. ncbi request reprint 160 years of multiple myeloma: progress and challenges
    Monika Engelhardt
    Eur J Cancer 42:1507-9. 2006